Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Benkert

Showing results (131-140 of 171) with videos related to

Pageof 18
Sort By:
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1994
Brief depression among patients in general practice. Prevalence and variation by recurrence and severityW Maier, R Herr, D Lichtermann, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1991
Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross-National Collaborative Panic StudyR Buller, W Maier, I M Goldenberg, et al.
Acta Psychiatrica Scandinavica|April 1, 1997
Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment responseO Benkert, A Szegedi, H Wetzel, et al.
Journal of Affective Disorders|July 1, 1991
Identification of minor affective disorders and implications for psychopharmacotherapyP Winter, M Philipp, R Buller, et al.
Journal of Psychiatric Research|July 1, 1995
Primary enduring negative symptoms in schizophrenia and major depressionH Gerbaldo, M P Fickinger, H Wetzel, et al.
Der Nervenarzt|June 1, 1993
[Panic disorder and vertigo. On the psychopathologic differentiation between neurologic and psychiatric disease]U Frommberger, S Hurth-Schmidt, H Dieringer, et al.
Pharmacopsychiatry|October 1, 1998
Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamineJ Sandmann, B Lörch, B Bandelow, et al.
Advances in Biochemical Psychopharmacology|January 1, 1974
The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patientsN Matussek, J Angst, O Benkert, et al.
Journal of Psychiatric Research|September 30, 1999
The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G)M J Müller, P Marx-Dannigkeit, R Schlösser, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1991
Subtyping panic disorder by major depression and avoidance behaviour and the response to active treatmentW Maier, R Rosenberg, N Argyle, et al.
Pageof 18

Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1994
Brief depression among patients in general practice. Prevalence and variation by recurrence and severityW Maier, R Herr, D Lichtermann, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1991
Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross-National Collaborative Panic StudyR Buller, W Maier, I M Goldenberg, et al.
Acta Psychiatrica Scandinavica|April 1, 1997
Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment responseO Benkert, A Szegedi, H Wetzel, et al.
Journal of Affective Disorders|July 1, 1991
Identification of minor affective disorders and implications for psychopharmacotherapyP Winter, M Philipp, R Buller, et al.
Journal of Psychiatric Research|July 1, 1995
Primary enduring negative symptoms in schizophrenia and major depressionH Gerbaldo, M P Fickinger, H Wetzel, et al.
Der Nervenarzt|June 1, 1993
[Panic disorder and vertigo. On the psychopathologic differentiation between neurologic and psychiatric disease]U Frommberger, S Hurth-Schmidt, H Dieringer, et al.
Pharmacopsychiatry|October 1, 1998
Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamineJ Sandmann, B Lörch, B Bandelow, et al.
Advances in Biochemical Psychopharmacology|January 1, 1974
The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patientsN Matussek, J Angst, O Benkert, et al.
Journal of Psychiatric Research|September 30, 1999
The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G)M J Müller, P Marx-Dannigkeit, R Schlösser, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 1, 1991
Subtyping panic disorder by major depression and avoidance behaviour and the response to active treatmentW Maier, R Rosenberg, N Argyle, et al.
Pageof 18